Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Jun 10;104(11):e213617.
doi: 10.1212/WNL.0000000000213617. Epub 2025 May 21.

Noninvasive Assessment of the Risk Features of Hemorrhage in Moyamoya Disease Using 7T MRI

Affiliations
Clinical Trial

Noninvasive Assessment of the Risk Features of Hemorrhage in Moyamoya Disease Using 7T MRI

Qi Duan et al. Neurology. .

Abstract

Background and objectives: While digital subtraction angiography (DSA) is traditionally used for moyamoya disease (MMD) assessment, its invasiveness and limitations necessitate alternative methods. The higher signal-to-noise ratio (SNR) and contrast-to-noise ratio of 7T MRI improve the clarity of the image and retains the details of the structures. We aimed to assess the performance of 7T MRI in identifying hemorrhagic risk features of MMD compared with 3T MRI and DSA.

Methods: This cross-sectional study recruited patients with MMD who underwent both 7T and 3T MRI scans within a 24-hour window, from March 2022 to December 2023. Patients were categorized into hemorrhagic, ischemic, and asymptomatic groups based on standard MRI findings and clinical symptoms. Corresponding DSA images acquired within 90 days were also collected as a comparative benchmark. Hemorrhage risk factors including dilatation and branch extension of the anterior choroidal artery (AChA) and posterior communicating artery (PComA) were assessed and graded on time-of-flight magnetic resonance angiography (TOF-MRA) and DSA images following established protocols. The hemorrhage locations were classified into anterior and posterior circulation groups.

Results: A total of 180 patients (mean age, 43.95 ± 11.02 [SD] years; 53.9% female) were included in the study (hemorrhagic = 51, ischemic = 37, asymptomatic = 92). Notably, 42.4% of AChA and 27.7% of PComA anomalies detected on 7T TOF-MRA were absent on 3T imaging. The 7T TOF-MRA demonstrated a strong correlation with DSA in assessing the AChA stage (weighted κ = 0.891, p < 0.001) and PComA stage (weighted κ = 0.761, p < 0.001). Higher AChA (70.6% vs 21.6% vs 6.5%, p < 0.001) and PComA (51.0% vs 8.1% vs 12.0%, p < 0.001) grades were more common in patients with hemorrhagic MMD compared with ischemic and asymptomatic groups. In binary logistic regression analysis for hemorrhagic and ischemic groups, elevated stages of AChA (odds ratio [OR] 1.90, 95% CI 1.20-3.54, p = 0.042) and PComA (OR 3.89, 95% CI 1.76-8.58, p = 0.001) were associated with increased hemorrhagic risk. Furthermore, the proportion of higher AChA (62.2%, p = 0.008) and PComA (51.3%, p = 0.010) grades were more prevalent in cases involving both anterior and posterior circulations.

Discussion: The 7T TOF-MRA visualization of dilatation and branching extension of the AChA and PComA indicates a heightened risk of hemorrhage, suggesting that this imaging technique could serve as a valuable noninvasive tool for identifying hemorrhagic vulnerabilities in MMD.

Trial registration information: ClinicalTrials.gov, NCT05287750, Brain Diseases on 7.0T Magnetic Resonance Imaging, First Submitted January 2022. clinicaltrials.gov/study/NCT05287750.

Classification of evidence: This study provides Class II evidence that 7T-TOF MRA accurately distinguishes hemorrhagic risk in patients with MMD compared with 3T-TOF MRA and DSA.

PubMed Disclaimer

Conflict of interest statement

The authors report no relevant disclosures. Go to Neurology.org/N for full disclosures.

Figures

Figure 1
Figure 1. Flow Diagram
Figure 2
Figure 2. Assessing Method of AChA and PComA Stages
(A) Grade 0: AChA invisible or normal (blue arrows); PComA, invisible or normal (green arrows). (B) Grade 1: AChA dilatation and extension within the choroidal fissure (blue arrows); PComA dilatation without abnormal extensive branches (green arrows). (C) Grade 2: AChA dilatation and extension beyond the choroidal fissure (blue arrows); PComA dilatation with abnormal extensive branches (green arrows). (D) Grade 3: AChA disappearance due to internal carotid artery occlusion (blue arrows); PComA disappearance due to internal carotid artery occlusion (green arrows). AChA = anterior choroidal artery; PComA = posterior communicating artery.
Figure 3
Figure 3. Comparison Between 7T TOF-MRA, 3T TOF-MRA, and DSA in the Visualization of the Anterior Choroidal Artery
(A–C) 7T TOF-MRA, 3T TOF-MRA, and DSA images of a patient with moyamoya disease. 7T TOF-MRA demonstrated superior performance to 3T while achieving comparable visualization of the left anterior choroidal artery (blue arrows) to DSA. DSA = digital subtraction angiography; TOF-MRA = time-of-flight magnetic resonance angiography.
Figure 4
Figure 4. Comparison Between 7T TOF-MRA, 3T TOF-MRA, and DSA in the Visualization of the Anterior Choroidal Artery and Posterior Communicating Artery
TOF-MRA images of 7T (A and B) and 3T (C and D) and DSA images (E and F) of a patient with moyamoya disease. 7T TOF-MRA demonstrated superior performance to 3T and provided comparable visualization of both the anterior choroidal artery (blue arrows) and posterior communicating artery (green arrows) relative to DSA. DSA = digital subtraction angiography; TOF-MRA = time-of-flight magnetic resonance angiography.
Figure 5
Figure 5. Comparison of Proportion of Each AChA and PComA Stage
AChA = anterior choroidal artery; DSA = digital subtraction angiography; MMD = moyamoya disease; PComA = posterior communicating artery; TOF-MRA = time-of-flight magnetic resonance angiography.

Similar articles

References

    1. Suzuki J, Takaku A. Cerebrovascular “moyamoya” disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969;20(3):288-299. doi:10.1001/archneur.1969.00480090076012 - DOI - PubMed
    1. Suzuki J, Kodama N. Moyamoya disease: a review. Stroke. 1983;14(1):104-109. doi:10.1161/01.str.14.1.104 - DOI - PubMed
    1. Kim JS. Moyamoya disease: epidemiology, clinical features, and diagnosis. J Stroke. 2016;18(1):2-11. doi:10.5853/jos.2015.01627 - DOI - PMC - PubMed
    1. Park EK, Lee YH, Shim KW, Choi JU, Kim DS. Natural history and progression factors of unilateral moyamoya disease in pediatric patients. Childs Nerv Syst. 2011;27(8):1281-1287. doi:10.1007/s00381-011-1469-y - DOI - PubMed
    1. Ferriero DM, Fullerton HJ, Bernard TJ, et al. . Management of stroke in neonates and children: a scientific statement from the American Heart Association/American Stroke Association. Stroke. 2019;50(3):e51-e96. doi:10.1161/str.0000000000000183 - DOI - PubMed

Publication types

Associated data